Carlsmed (CARL) EBIT (2024 - 2026)

Carlsmed (CARL) has reported EBIT for 3 consecutive years, with -$11.0 million the latest figure, recorded in Q2 2026.

• For the quarter ending Q2 2026, EBIT fell 69.73% year-over-year to -$11.0 million; the trailing twelve-month figure through Jun 2026 stood at -$38.7 million (down 56.57% YoY), and the FY2025 full-year result was -$30.6 million, down 26.75% from the prior year.
• EBIT declined to -$11.0 million in Q2 2026 per CARL's latest filing, from -$9.3 million in the prior quarter.
• Across five years, EBIT topped out at -$4.7 million in Q4 2024 and bottomed at -$11.0 million in Q2 2026.
• Historically, EBIT has averaged -$7.7 million across 3 years, with a median of -$7.8 million in 2024.
• The widest YoY moves for EBIT: up 2.9% in 2025, down 98.38% in 2025.
• Over 3 years, EBIT stood at -$4.7 million in 2024, then sank by 98.38% to -$9.3 million in 2025, then decreased by 18.44% to -$11.0 million in 2026.
• According to Business Quant data, EBIT over the past three periods registered -$11.0 million, -$9.3 million, and -$9.3 million for Q2 2026, Q1 2026, and Q4 2025 respectively.